A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and
 ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as
 dasabuvir) co-administered with ribavirin (RBV) in hepatitis C virus genotype 1 infected
 treatment-experienced adults.
Inclusion Criteria:

 -  Females must be post-menopausal for at least 2 years or surgically sterile or
 practicing specific forms of birth control.

 -  Chronic hepatitis C, genotype 1 infection and HCV RNA level greater than 10,000 IU/mL
 at screening.

 -  Previous treatment failure of peg-interferon and ribavirin (pegIFN and RBV).

 -  No evidence of liver cirrhosis.

 Exclusion Criteria:

 -  Positive screen for drugs or alcohol.

 -  Significant sensitivity to any drug.

 -  Use of contraindicated medications within 2 weeks of dosing.

 -  Certain predefined abnormal laboratory tests.

 -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody.